Patients:
The current study was a cohort clinical trial. It was conducted between May 2018 and December 2019 on sixty patients with CLP who were enrolled in the Outpatient Clinics at Dermatology Department, Faculty of Medicine, Faculty of Medicine, South Valley University between May 2018 and December 2019. The study received the approval of Scientific and Ethics Committees at the Faculty of Medicine, South Valley University. Informed consent was taken from the participants after detailed clarifications of the nature of this study.
.
Inclusion criteria: Patients with CLP diagnosed clinically.
Exclusion criteria: CLP patients with other autoimmune diseases like systemic lupus, rheumatoid or mixed connective tissue diseases, alcoholic diseases, heart diseases or liver diseases, blood cell disorders such as anemia or leucopenia, bone marrow dysfunction, nursing or pregnant women, kidney disease, infants or children, photo-exaggerated patients, previous NB-UVB therapy or systemic therapy in 6 months prior to the first LP therapy, history of dysplastic nevi, malignant skin lesions, and drug-treated patients causing photosensitivity or cutaneous pigmentations within 60 days before the initiation of NB- UVB therapy.